IMU Imugene Ltd
- 0.082
- +0.003+3.80%
Imugene Ltd News
Those Who Invested in Imugene (ASX:IMU) Five Years Ago Are up 361%
Broker Says This ASX Biotech Stock Could Almost Double in Value
If you're the type of investor that likes high risk-high reward investments, then read on.
Imugene Signs Deal to Sell Manufacturing Facility For $6 Million
Imugene (ASX:IMU) signed a deal to sell its manufacturing facility in North Carolina to contract development and manufacturing organization Kincell for a total of $6 million, according to a Tuesday fi
AU Morning Wrap: ASX Falls in All Sectors; Star Plunges
Stocks to watch: Macquarie Technology, Imugene, Hub24.
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study
Immuno-oncology company Imugene (ASX:IMU) said it has opened enrolment for its expansion study in patients with bile tract cancer or cholangiocarcinoma, according to a Monday filing with the Australia
Press Release: Imugene's Oncolytic Virotherapy VAXINIA and B Cell Immunotherapy HER-Vaxx Featured at the AACR Annual Meeting 2024
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 -- Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA
Imugene Shines at AACR With Promising Cancer Therapy Results From VAXINIA and HER-Vaxx
|Clinical stage immuno-oncology company Imugene Ltd (ASX:IMU, OTC:IUGNF) is showcasing its leading therapies, VAXINIA and HER-Vaxx, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego from April 5-10.
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China
Imugene (ASX:IMU) has received the Chinese patent for oncolytic virotherapy CF33 for cancer treatment, the company said in a Thursday filing with the Australian Securities Exchange. The patent, which
Imugene Has VAXINIA Technology Selected for Presentation at Cholangiocarcinoma Foundation Conference | ASX:IMU, OTC:IUGNF
Arovella Therapeutics' ALA-101-onCARlytics Collaboration With Imugene Ends; Shares Down 12%
Arovella Therapeutics (ASX:ALA) said its collaboration with Imugene (ASX:IMU) to combine ALA‐101 and onCARlytics has ended, effective immediately, according to a Wednesday filing with the Australian S
Imugene's Phase 1 OnCARlytics Trial to Commence Combination Arm Treatment
Immuno-oncology company Imugene (ASX:IMU) said phase 1 clinical trial of CD19 oncolytic virotherapy drug candidate onCARlytics is scheduled to commence combination dosing solid tumor patients with CD1
Imugene's OnCARlytics Clears Phase 1 Milestone in Solid Tumour Therapy Trial
Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that a Phase 1 clinical trial of lead drug candidate onCARlytics has cleared its first cohort within the intra-tumoural monotherapy arm of the study.
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending
Imugene (ASX:IMU) reported Thursday that it widened its loss per share in the six-month period ended Dec. 31, 2023, to AU$0.0100, versus the prior-year period's AU$0.0028. The immunotherapy developer
Imugene Reports H1 FY24 Loss Widens as Expenses Grow
05:54 PM EST, 02/28/2024 (MT Newswires) -- Imugene Reports H1 FY24 Loss Widens as Expenses Grow Price (AUD): $0.12, Change: $0.00, Percent Change: +4.35%
Why Are ASX Tech Shares Booming on Friday?
It's been a fairly lucrative day for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares so far this Friday.
Imugene's Phase 1 OnCARlytics Trial Doses First Patient in Intravenous Monotherapy Arm
Immuno-oncology company Imugene (ASX:IMU) said its CD19 oncolytic virotherapy drug candidate, onCARlytics, has dosed the first patient in the intravenous monotherapy arm of the phase 1 OASIS clinical
Medicare Levy Change: 1.2 Million Aussies to Get Extra Tax Boost
Millions of Aussies will be able to avoid or pay a lower Medicare levy under a major change announced by the government.
AU Evening Wrap: Australia Shares Slip 0.6% as RBA Holds Rates
Tech was the worst-performing of the ASX 200's 11 sectors, shedding 1.8%.
AU Evening Wrap: Australia Shares Rise 1.1% to First Record Close Since August 2021
Financials, the largest of the ASX 200's 11 sectors, rose 1.5%.
Australia's Q4 Inflation Rate Eases to 0.6%, Falling Below Expectations
The CPI slowed to 0.6% in the December quarter, down from 1.2% in the previous quarter. Market consensus was 0.8%.
Analysis
Price Target
No Data
